Unveiling Liquid Gold: Lymph as an HPV Marker in OPSCC to Guide Treatment Decisions.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38252056.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3549.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Distinguishing low- versus high-risk HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is pivotal for tailoring treatment. Liquid biopsy, measuring cell-free HPV-DNA in serum and saliva, assesses treatment response and early-recurrence risk. Postoperative lymphatic fluid may better guide future adjuvant therapy decisions due to its proximity to primary lesions and lymph nodes. See related article by Earland et al., p. 1409.
Medical subject headings
- Carcinoma, Squamous Cell
- Oropharyngeal Neoplasms
- Papillomavirus Infections
- Head and Neck Neoplasms